The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Diagnosing & Treating Hemophagocytic Lymphohistiocytosis in Adults

Diagnosing & Treating Hemophagocytic Lymphohistiocytosis in Adults

June 15, 2020 • By Srujana Pachigolla, MD, & Adegbenga Bankole, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
An activated macrophage.

An activated macrophage.
David Scharf/Science Source

Primary hemophagocytic lymphohistiocytosis (HLH) is caused by genetic mutations and inherited syndromes; it therefore occurs in the pediatric age group. Secondary HLH, however, is more common in adults and is often triggered by other disease states, such as malignancies, chronic immuno­suppression, infections and autoimmune disease.1,2 Macrophage activation syndrome (MAS) is a subset of secondary HLH seen in patients with autoimmune diseases, such as systemic juvenile idiopathic arthritis (sJIA), systemic lupus erythematosus (SLE) and adult-onset Still’s disease.3

You Might Also Like
  • Fellows’ Forum Case Report: Hemophagocytic Lymphohistiocytosis
  • Case Report: Diagnosing, Treating Hepatitis B-Linked Polyarteritis Nodosa
  • Tips for Diagnosing, Treating Seldom Seen Forms of Vasculitis
Explore This Issue
June 2020

A high index of suspicion for HLH is crucial because treatment delay is associated with high mortality and morbidity. Excluding other causes of the symptoms also prevents inappropriate treatment, which can lead to poor outcomes.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Case Presentation

A 69-year-old woman was admitted with a one-week history of fever. She reported at least two temperature spikes daily, which were associated with chills but not rigors.

She noted two to three days of nausea, decreased appetite, pharyngitis, frontal headaches and arthralgias that migrated between her neck, shoulders, ankles and knees. She also had a cough, productive of clear phlegm and associated with exertional shortness of breath.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The patient had a 14-year history of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV). She had presented with glomerulonephritis, which was treated with cyclophosphamide and glucocorticoids, followed by azathioprine. She reported that her current complaints were similar to the symptoms she experienced when she was first diagnosed with AAV.

LAB VALUEDay 1Day 2
Sodium (135–145 mmol/L)129 mmol/L (L)132 mmol/L (L)
Carbon dioxide (21–32 mmol/L)22 mmol/L22 mmol/L
BUN (7–18 mg/dL)22 mg/dL(H)24 mg/dL (H)
Creatinine (0.60–1.30 mg/dL)1.60 mg/dL(H)1.7 mg/dL (H)
Lactic acid (0.36–1.7 mmol/L)1.64 mmol/L
AST (15–37 U/L)522 U/L (H)717 U/L (H)
ALT (13–61 U/L)228  U/L (H)292 U/L (H)
Alk Phosphatase (45–117 U/L)168 U/L (H)163 U/L (H)
Albumin (3.4–5.0 mg/dL)2.8 mg/dL (H)2.6 mg/dL (L) 
WBC (4.5–10.5 10*3/uL)3.96 K/uL (L)3.92 K/uL( L)
Band neuts % (2–8%)0.0314% (H)
Hgb (11.4–15.5 g/dL)11.6 g/dL (L)10.9 g/dL (L)
Hct (37.0–47.0%)32.2% L31.0% L
Platelet count (130–385 10*3/uL)38 K/uL (L)36 K/uL (L)
ESR (0–20 mm/HR)22 mm/HR (H)
CRP (<0.300 mg/dL)18.1mg/dL (H)
Total creatinine kinase (21-215 U/L)156 U/L
LDH (84–246 U/L)1,275 U/L (H)
Monoscreen Negative
Influenza Type A and B AgNegative
Hepatitis panel (Hepatitis A IgM, HBsAg, Hep B Core IgM, Hepatitis C AbNegative
HIV 1&2 AntibodyNegative
HIV p24 AntigenNegative

Her home medication use included azathioprine 100 mg daily, amlodipine 5 mg daily and 25 mg of metoprolol twice daily.

At the time of presentation, her temperature was 102.6° F, and she had a blood pressure of 83/63 mmHg and a heart rate of 102/minute. Her respiratory rate was 19 breaths/minute with oxygen saturation of 93% on room air.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

She was oriented, but appeared uncomfortable. Her mucosal membranes were dry, and she was tachycardiac; her examination was otherwise not revealing.

Her laboratory tests were consistent with shock (see Table 1, left). A computerized tomography (CT) scan of her chest demonstrated small pleural effusions with bibasilar infiltrates, but no lymphadenopathy. An abdominal ultrasound confirmed her liver was grossly unremarkable, with no dilatation of the common bile duct, no gall stones, ascites or splenic enlargement.

Diagnosis & treatment: Her admitting diagnosis was septic shock, and she was treated with intravenous vancomycin and cefepime. An infectious disease specialist was consulted to evaluate the patient for atypical infections. The patient’s blood and urine cultures did not identify an organism, so she was transitioned to azithromycin.

During her admission, she had a persistent, high-grade fever, with a maximum temperature of 103.6° F. Her respiratory status continued to worsen, with tachypnea and hypoxia requiring increasing oxygen supplementation. Her laboratory test demonstrated leukopenia, bandemia, thrombocytopenia, transaminasemia and declining renal function. She was noted to have a discordance between her erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), and tests for infectious etiologies, including viral hepatitis, human immunodeficiency virus and parvovirus were all negative.

She was treated empirically with 500 mg of intravenous methylprednisolone to address the possibility that she was experiencing a relapse of her underlying rheumatic disease, and she was transferred to our center for rheumatology input.

Upon arrival, she was noted to have a persistent fever and respiratory distress; she was tachypneic and was using accessory muscles despite high-flow oxygen therapy. She was subsequently intubated for respiratory failure.

A repeat chest X-ray showed worsening bilateral pulmonary infiltrates, and she was restarted on vancomycin, cefepime and doxycycline. She was also given pulse-dose methyl­prednisolone 1 gm daily for three days.

Further laboratory testing (see Table 2, below) again showed discordance between her ESR and CRP, prompting the consideration of alternative diagnoses to sepsis and vasculitis. Bronchoalveolar lavage failed to demonstrate evidence of diffuse alveolar hemorrhage (DAH), infection or malignancy. She sub­sequently developed altered mental status, which was not felt to be due to infection or non-convulsive status epilepticus.

LAB COMPONENTday 3
Sodium (135–145 MMol/L)139 MMol/L
BUN (6–20 mg/dL)31 mg/dL (H )
Creatinine (0.5–1.2 mg/dL)1.99 mg/dL (H)
AST (10–42 IU/L)626 IU/L (H)
ALT (10–60 IU/L)245 IU/L (H)
ALP (42–121 IU/L)175 IU/L (H)
WBC (4.0–10.5 K/uL)4.6 K/uL
Hemoglobin (12.0–16.0 g/dL )11.5 g/dL (L)
Hematocrit (36–46%)31.7% (L)
Platelets (130–400 K/uL)50,000 K/uL (L)
ESR (0–30 mm/HR)5 mm/HR
CRP (<1.0 mg/dL)14.9 mg/dL (H)
LDH (135–214 IU/L)2010 IU/L (H)
Ferritin (13–150 ng/mL)54,059 ng/mL (H)
Triglycerides (<150 mg/dL)638 mg/dL (H)
Fibrinogen (204–475 mg/dL)199 mg/dL (L)
ANCA screen (C-ANCA and P-ANCA titer)Negative
Rheumatoid factor<14 IU/mL
Ribosomal protein<1.0 NEG AI
Anti-DNA, native double strand<1 IU/mL
Sm/RNP<1.0 NEG AI
Scleroderma (SCL-70)<1.0 NEG AI
Sjögren’s antibody SSA<1.0 NEG AI
Sjögren’s antibody SSB<1.0 NEG AI
Anti-Smith antibody<1.0 NEG AI
Anti-centromere B antibody<1.0 NEG AI
Anti Jo-1 antibody<1.0 NEG AI
Anti-Streptolysin O<50 Ref: <200 IU/mL
Anti-nuclear antibodyNegative
CCP Ab IgG77 H, Ref: strong positive >59
Complement C370 L, Ref: 90–180 mg/dL
Complement C432.8, Ref: 10–40 mg/dL
Thyroid peroxidase (TPO) Ab<1, Ref: <9 IU/mL

A bone marrow biopsy was obtained and demonstrated a clonal T cell population, with megakaryocytic hyperplasia and rare hemophagocytosis (see Figure 1, opposite). Serum soluble interleukin (IL) 2 receptor (IL-2R) levels were elevated at 10,219 pg/mL (reference range 532–1,891 pg/mL).

A diagnosis of HLH was made, and the antibiotics were stopped. The patient was subsequently treated with 112.5 mg/m2 etoposide (corrected based on renal function) twice weekly for two weeks and 20 mg of intravenous dexamethasone daily for two weeks, after which she gradually improved. She was subsequently extubated, with improvement in mental status, although she still has some memory issues.

She was eventually discharged to a subacute facility for inpatient rehabilitation, where she received 112.5 mg/m2 etoposide weekly for three weeks and 150 mg/m2 of etoposide (corrected based on renal function) weekly for three weeks. She also received dexamethasone, which was tapered from 10 mg daily for two weeks to 5 mg daily for two weeks to 2.5 mg daily for two weeks to 1.25 mg daily for one week, before being discontinued.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Vasculitis Tagged With: case report, hemophagocytic lymphohistiocytosis, hemophagocytic lymphohistiocytosis (HLH), HLH, macrophage activation syndromeIssue: June 2020

You Might Also Like:
  • Fellows’ Forum Case Report: Hemophagocytic Lymphohistiocytosis
  • Case Report: Diagnosing, Treating Hepatitis B-Linked Polyarteritis Nodosa
  • Tips for Diagnosing, Treating Seldom Seen Forms of Vasculitis
  • Clinical Pearls for Diagnosing & Treating Sjögren’s Syndrome

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.